IBB-Institute for Biotechnology and Bioengineering, Centre for Molecular and Structural Biomedicine (CBME), University of Algarve, Campus de Gambelas, 8005-139 Faro, Portugal; Regenerative Medicine Program, Department of Biomedical Sciences and Medicine,University of Algarve, Campus de Gambelas, 8005-139 Faro, Portugal, walink@ualg.pt
References
[1] Drews J., Drug discovery: a historical perspective, Science,2000, 287, 1960-1964
[2] Vane J.R., Inhibition of prostaglandin synthesis as amechanism of action for aspirin-like drugs, Nat. New Biol. 1971,231, 232-235
[3. Kauselmann G., Dopazo A., Link W., Identification of diseaserelevantgenes for molecularly-targeted drug discovery, Currentcancer drug targets, 2012, 12, 1-13
[4] Benson J.D., Chen Y.N., Cornell-Kennon S.A., Dorsch M., Kim S.,Leszczyniecka M., et al., Validating cancer drug targets, Nature,2006, 441, 451-456
[5] Kola I., Landis J., Can the pharmaceutical industry reduceattrition rates? Nature reviews Drug discovery, 2004, 3, 711-715
[6] Link W., Madureira P.A., Hill R., Identifying new targetsfor personalized medicine, eLS, John Wiley & Sons, Ltd:Chichester, 2013, DOI: 10.1002/9780470015902.a0024865[Crossref]